Clinical Trials in China / NCT07524959
Starting soon
Not applicable
Antagonism of Neostigmine in Continuous Infusion of Mivacurium
NCT07524959 · tracked via the Priya Life Science China tracker
Condition(s) studied
Neuromuscular Blocking Agents
Investigational drug(s) / intervention(s)
Neostigmine: Administer neostigmine at a dose of 0.04 mg/kg (combined with 0.02 mg/kg atropine)
Study summary
In this study, the antagonism of neostigmine, a cholinesterase inhibitor, on continuous infusion of mivacurium during foot and ankle surgery under general anesthesia was investigated, and the appropriate time point of antagonism was explored.
Eligibility
Inclusion Criteria:
* 18 - 65 years old;
* American Society of Anesthesiologists (ASA) physical stastus classification system: I-II;
* Body mass index (BMI) 18.5 - 30 kg/m2
* Patients with normal cholinesterase levels before the operation
Exclusion Criteria:
* Refusal to participate in the study;
* ASA classification of grade III or above;
* Severe organ dysfunction, difficult airway or neurological muscle disorders;
* Taking drugs that affect neuromuscular monitoring or neuromuscular conduction function;
* Allergic to the test drug or having other contraindications;
* Pregnant and lactating women
Primary outcome measure(s)
- The time from count 2 to TOFr recovery to 0.9 — Perioperative
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing tongren Hospital, Capital Medical University | Beijing | Beijing Municipality |
More Beijing Tongren Hospital trials in China
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07524959 on ClinicalTrials.gov ↗ ← All trials in China